# A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

> **NCT01473420** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 320 (actual)

## Conditions studied

- Chronic Renal Failure
- Chronic Kidney Disease

## Interventions

- **BIOLOGICAL:** Epoetin Hospira
- **BIOLOGICAL:** Epogen Amgen

## Key facts

- **NCT ID:** NCT01473420
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2014-02-28
- **Final completion:** 2014-02-28
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473420, "A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01473420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*